Excellims Ion-Mobility Separator Interfaces with Mass Spectrometers
The MA3100 high performance ion mobility pre-separator (HPIMS) from Excellims has been built to interface with multiple mass spectrometer (MS) product lines from Thermo Fisher Scientific.
The MA3100 high performance ion mobility pre-separator (HPIMS) from Excellims has been built to interface with multiple mass spectrometer (MS) product lines from Thermo Fisher Scientific. The MA3100 enhances MS technology by increasing versatility, simplifying complex spectra, and allowing targeted analysis of gas phase ions.
The HPIMS-Orbitrap MS combination delivers ultra-high-resolution separation of complex samples in both ion mobility and m/z domains and provides information about the structure and identity of molecular ions. The MA3100 is exchangeable with the current ionization sources of the MS. The technology attains high-resolution separation that has not been possible on previously existing systems and routinely performs separations with a resolving power of more than 70.
ref="http://www.excellims.com" target="_blank" ref="nofollow">Excellims
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
